In the past months, BioLingus has been discussing concrete projects with potential partners in this area, which are listed below as examples :
• Project 1 : sublingual administration of anti-IL23 domain antibodies against Crohn's disease and psoriasis ; this product would take market share from amongst others Stelara (ustekinumab) – expected to sell over 1.4 B USD in 2016;
• Project 2 : SL administration of anti-TNF-alfa peptides against Rheumatoid arthritis ; this product would take a market share from Remicade (infliximab), which is currently selling about 5.0 B USD annually. It is in the same indication as Humira, which is selling 10 B USD per year and Enbrel, which sold 8.7 B USD. Furthermore, an oral version of this product could expand the market to for instance more mild version or RA, which cannot be addressed with the injectable products ;
• Project 3 : low dose interleukin-2 to treat juvenile type-1 diabetes and allergy (feasibility study ongoing) ;
• Project 4 : peptide vaccine against diabetes ;
• Project 5 : sublingual survivin-peptide vaccine to treat multiple cancers (this is a dentritic cell vaccine).
This latter project is in the area of immuno-oncology, which is currently one of the most promising areas in the treatment of cancer.
This is achieved by manipulating immune cells and stimulating specific components of the system or by counteracting cancer cell "avoidance" signals that suppress immune responses.
Immune‐modifying agents work through different mechanisms. Cytokines such as interferons and interleukins are signalling proteins produced by white blood cells, such as natural killer cells and dendritic cells, to help regulate immune responses.